AbbVie is one of America's most prominent biopharmaceutical companies, spun out of Abbott Laboratories in 2013 and built around a commercial drug portfolio of considerable scale and reach. Listed on the NYSE under the ticker ABBV, the company is perhaps best known as the maker of Humira, for many years the world's best-selling prescription medicine, though its strategic priority in recent years has been diversifying beyond Humira as biosimilar competition has eroded that franchise.
The diversification effort has been substantial. AbbVie's acquisitions of Allergan and a series of oncology and immunology assets have broadened the pipeline meaningfully, with Skyrizi and Rinvoq emerging as the next generation of growth drivers. For traders, AbbVie is an interesting combination of defensive pharmaceutical income: the company has a strong dividend track record and binary event risk around clinical trial outcomes and regulatory decisions that can move the share price sharply in either direction.
Please note this is marketing communication, not recommendation or advice.
client accounts
FxPro has been providing online trading services to clients since 1999 and it currently serves 173 countries worldwide.
Awards
FxPro has received constant recognition in the industry, winning over 145 international awards to date for the quality of its services.
customer service
Our dedicated, multilingual customer service team works 24/5 to provide you with an exceptional level of support.
industry regulations
FxPro operates under strict regulatory oversight across multiple jurisdictions, including authorisation by the FCA in the UK — one of the most trusted financial regulators globally.
